There's no doubting. Everolimus is a drug which has a wide range of use. It's pretty incredible the amount of indications which it is being tested and has already been proven to work.
I think the vast majority of the trials are now in combination studies (which I am insistent that mTORs will find their greatest success).
If you have any results of their trials in single-agent sarcoma studies handy (other than GIST), I would love to see them - because, to my knowledge, they were anything but great, and rather similar to Ariad's.
News 
Market Data 
Discover 
AI
